SCHEDULE 13D/A: Malone Wealth Ventures Increases Stake in Quantum Biopharma to 17%, Advisor Kevin Malone Expands Influence

Malone Wealth Ventures LLC and its President Kevin Malone have increased their beneficial ownership in Quantum Biopharma Ltd. to 17% through open market purchases and compensation grants, indicating potential influence over the issuer's strategic direction.

Summary

• Malone Wealth Ventures LLC and Kevin Malone beneficially own 580,806 shares of Quantum Biopharma Ltd. Common Stock, representing 17.0% of the class.
• The shares were acquired through open market purchases using client funds over which Malone Wealth Ventures LLC has discretionary investment authority.
• Kevin Malone received an initial grant of 30,000 shares and an additional 60,000 shares as compensation for his role as Advisor to the Board of Directors of Quantum Biopharma Inc.
• The purpose of the acquisition is for investment, and Kevin Malone, as an Advisor to the Board, may participate in discussions regarding strategic direction, financing, capitalization, or corporate governance.
• Malone Wealth Ventures LLC executed numerous open market purchases of Quantum Biopharma Ltd. Common Stock on behalf of advisory clients between June 13, 2025, and June 20, 2025, with prices ranging from $18.80 to $37.59 per share.

Sentiment

Score: 7

Explanation: The document indicates a significant and growing investment by an advisory firm and its principal, with the principal taking an advisory role on the board, suggesting a positive outlook and potential for strategic influence. The consistent open market purchases at increasing prices also reflect confidence.

Positives

• Increased beneficial ownership by an investment advisory firm and its CEO, potentially signaling confidence in the company's future.
• Kevin Malone, President and CEO of Malone Wealth Ventures LLC, serves as an Advisor to the Board, providing an experienced financial perspective and potential for strategic input.
• Significant open market purchases by Malone Wealth Ventures LLC on behalf of clients, indicating active investment interest and a willingness to acquire shares at varying price points.

Risks

• Reporting Persons may, from time to time, acquire additional securities of the issuer or dispose of some or all of the reported securities, depending on market conditions, investment strategies, or other factors, which could impact share price volatility.

Future Outlook

Reporting Persons may, from time to time, acquire additional securities of the issuer or dispose of some or all of the securities reported herein, depending on market conditions, investment strategies, or other factors. No other grants have been discussed for the future at this time.

Management Comments

• The securities were acquired for investment purposes.
• Kevin Malone serves as Advisor to the Board of Directors of the issuer and may, in such capacity, participate in discussions relating to strategic direction, financing, capitalization, or corporate governance.
• Reporting Persons may, from time to time, acquire additional securities of the issuer or dispose of some or all of the securities reported herein, depending on market conditions, investment strategies, or other factors.
• At this time, no other grants have been discussed in the future.

Industry Context

This filing primarily concerns a change in beneficial ownership and potential influence by an investment advisory firm in a biopharma company. It does not provide specific details on broader industry trends within the biopharma sector, but increased institutional or advisory firm stakes can sometimes signal growing interest in a particular company within its industry.

Management Changes

Corporate Governance

Related Party Transactions

• Kevin Malone received a grant of 30,000 shares as compensation for his role as Advisor to the Board of Directors of Quantum Biopharma Inc., pursuant to a consulting agreement.
• An additional 60,000 share grant was received by Kevin Malone based on continuation of work.

Stakeholder Impact

• Shareholders: Increased ownership by an investment firm and an advisor to the board could be seen positively, potentially signaling confidence and providing a voice for investor interests in strategic discussions. However, the possibility of future dispositions by the reporting persons could introduce volatility.
• Management/Board: The presence of an Advisor to the Board from a significant investor could lead to increased scrutiny or influence on strategic and governance decisions.

Next Steps

• Reporting Persons may acquire additional securities of the issuer.
• Reporting Persons may dispose of some or all of the securities reported herein.

Key Dates

Recommendation

Keywords

Quantum Biopharma Ltd., Malone Wealth Ventures LLC, Kevin Malone, Schedule 13D, beneficial ownership, investment advisory, common stock, corporate governance, strategic direction, SEC filing, biopharma